Tuesday, 21 May 2019

Plenary Session
09:45 - 10:00

Welcome Address
Welcome
Speaker: Christoph Huber (CIMT, Mainz, Germany)

Plenary Session
10:00 - 11:30

Counteracting Immune Escape
Chair: Sjoerd H. van der Burg (Leiden University Medical Center, Leiden, Netherlands)
Chair: Carl Figdor (Radboud University Medical Center, Nijmegen, Netherlands)

Genomic evaluation of tumor immune cells to steer treatment choices
Speaker: Christian Ottensmeier (University of Southampton, Southampton, United Kingdom)
10:00 - 10:30

A new look at T-cell exhaustion: Implications for immunotherapy
Speaker: Rafi Ahmed (Emory Vaccine Center, Atlanta, United States)
10:30 - 11:00

BH4 – a critical new metabolite for T cell proliferation
Speaker: Josef Penninger (University of British Columbia, Vancouver, Canada)
11:00 - 11:30

Lunch Break
11:30 - 13:30

Lunch Break

Plenary Session
12:00 - 13:00

Chemical Immunology
Chair: Mustafa Diken (TRON, Mainz, Germany)
Chair: Martijn Verdoes (Radboud University Medical Center, Nijmegen, Netherlands)

TLR-ligand conjugated synthetic peptide cancer vaccines
Speaker: Ferry Ossendorp (Leiden University Medical Center, Leiden, Netherlands)
12:00 - 12:20

pH-degradable polymeric nanogels for local and systemic cancer immunotherapy
Speaker: Lutz Nuhn (Max Planck Institute for Polymer Research, Mainz, Germany)
12:20 - 12:40
Development of personalized cancer nanovaccines against neoantigens 12:40 - 13:00
Speaker: Li Tang (École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland)

CIMT Members Meeting 12:00 - 13:00 North Foyer Hall

CIMT Members Meeting

Plenary Session 13:30 - 15:00 Gutenberg Hall

Neoantigens and Tumor Evolution
Chair: Hans-Georg Rammensee (University of Tübingen, Tübingen, Germany)
Chair: Michal Bassani-Sternberg (UNIL/CHUV, Epalinges, Switzerland)

The molecular cell biology of immune control and escape of cancer 13:30 - 14:00
Speaker: Robert Schreiber (Washington University School of Medicine, St. Louis, United States)

More insights on neoantigen-specific T cells 14:00 - 14:30
Speaker: George Coukos (University Hospital Lausanne, Lausanne, Switzerland)

Lung cancer evolution and immune escape 14:30 - 15:00
Speaker: Nicholas McGranahan (Cancer Research UK Lung Cancer Centre of Excellence, London, United Kingdom)

Coffee Break 15:00 - 17:00 Exhibition Hall

Coffee Break

Poster Session 15:00 - 17:30 Exhibition Hall

Poster Session - Immunomonitoring

Murine NK cells acquire a dysfunctional phenotype during interaction with MHC class I deficient solid tumors
Speaker: Jan David Beck (TRON - Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH, Mainz, Germany)

High dimensional proteomic profiling of immune cell subsets with data-independent acquisition mass spectrometry
Speaker: Kristina Beeler (Biognosys AG, Schlieren, Switzerland)

Deciphering the mechanisms of efficacy and toxicity of checkpoint inhibitors in cancer patients
Speaker: Fiamma Berner (Kantonsspital St. Gallen, St. Gallen, Switzerland)

Sensitive monitoring of CAR+ T cells in peripheral blood by flow cytometry and transgene RT-qPCR
Speaker: Stefanie Biedermann (Mitenyi Biotec GmbH, Bergisch Gladbach, Germany)

Polymorphic T cell responses against a shared clonal driver mutation in astrocytoma
Speaker: Lukas Bunse (German Cancer Research Center (DKFZ), Heidelberg, Germany)
Immunotoxicity assessment in a circulating human whole blood system
Speaker: Erika Fletcher (Immuneed AB, Uppsala, Sweden)

MHC multimer proficiency panel 2018
Speaker: Katrine Frederiksen (Immudex, Copenhagen, Denmark)

Elispot proficiency panel 2019
Speaker: Charlotte Halgreen (Immudex, Copenhagen, Denmark)

Skin adverse events during immune checkpoint inhibitor treatments correlate with frequency of tumor somatic mutations in skin-enriched genes
Speaker: Omar Hasan Ali (University Hospital Zurich, Zurich, Switzerland)

Prediction of irAEs in Ipilimumab-treated melanoma patients based on serum autoantibodies
Speaker: Jessica Hassel (University Hospital Heidelberg, Heidelberg, Germany)

PepSupTM: a highly standardised, peptide-based ex-vivo stimulation assay for antigen-specific whole blood profiling
Speaker: Pavlo Holenya (JPT Peptide Technologies GmbH, Berlin, Germany)

Dissecting T-cell responses in vaccinated, long-term surviving glioblastoma patients
Speaker: Else Marit Inderberg (Oslo University Hospital- The Norwegian Radium Hospital, Oslo, Norway)

Radiotherapy combined with the immunocytokine L19-IL2 alters the systematic and tumor-infiltrating immune compartments
Speaker: Mohammad Kadivar (Technical University of Denmark - DTU, Kgs. Lyngby, Denmark)

Evaluating a single domain antibody specific for human PD-L1 as a cancer nuclear imaging and therapy agent
Speaker: Quentin Lecocq (Vrije Universiteit Brussel, Jette, Belgium)

CD73 immune checkpoint defines inducible regulatory NK cells in the tumor microenvironment
Speaker: Andreas Lundqvist (Karolinska Institutet, Stockholm, Sweden)

Cellular Immunomonitoring for the personalized adoptive cellular therapy trial ACTolog® IMA101-101
Speaker: Anna Nowak (Immatics Biotechnologies GmbH, Tübingen, Germany)

Immunosuppressive capacity of myeloid-derived suppressor cells and neutrophils in melanoma patients treated with immune checkpoint inhibitors
Speaker: Vera Petrova (University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, German Cancer Research Center (DKFZ), Mannheim, Germany)

Neoadjuvant radiochemotherapy significantly alters the phenotype of human plasmacytoid dendritic cells and 6-sulfo LacNAc+ monocytes in rectal cancer
Speaker: Ioana Plesca (TU Dresden, Medical Faculty Carl Gustav Carus, Institute of Immunology, Dresden, Germany)

Characterization of gene expression biomarkers for predicting immunotherapy in Thai metastatic breast cancer
Speaker: Siripakorn Sangkitporn (Medical Life Sciences Institute, Nonthaburi, Thailand)

RhoC vaccination induces a robust and long-lasting immune response in a clinical phase I/II prostate cancer trial
Speaker: Juliane Schuhmacher (University of Tübingen, Tübingen, Germany)

Poster Session - Cellular Therapy

Vy9V62 T cells for adoptive cell transfer benefit from expansion with IL-15
Speaker: Pia Aehnlich (University Hospital Herlev, Center for Cancer Immune Therapy, Department of Hematology, Herlev, Denmark)
In vivo generated human CAR T cells eradicate tumor cells
Speaker: Shiwani Agarwal (Paul Ehrlich Institute, Langen, Germany)

A combinatorial IGL-CD19 CAR provokes unpredicted cytotoxicity
Speaker: Elizabeth Baken (Oslo University, Hospital Radiumhospitalet, Oslo, Norway)

Dissecting the T cell receptor interactions governing recognition of peptide-MHC complexes
Speaker: Amalie Kai Bentzen (Technical University of Denmark, Lyngby, Denmark)

Fully automated clinical scale isolation of blood derived panDCs for the generation of cancer vaccines
Speaker: Eva Bergschneider (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)

Viral and non-viral Sleeping Beauty (SB) transposition-based engineering of chimeric antigen receptor NK cells for treatment of acute lymphoblastic leukemia
Speaker: Tobias Bexte (Experimental Immunology, Hospital of the Goethe University Frankfurt, Frankfurt am Main, Germany)

In vitro generation of tumor antigen-specific T-cells from healthy donor and patient stem cells
Speaker: Sarah Bonte (Ghent University, Ghent, Belgium)

HA-1-specific T-cell receptors for the treatment of hematological malignancies
Speaker: Aline Bracher (Medigene Immunotherapies GmbH, Martinsried/Planegg, Germany)

Antimelanoma activity of HLA-independent immune effectors redirected by anti-CSPG4 chimeric-antigen receptor (CAR)
Speaker: Giulia Cattaneo (University of Turin, Department of Oncology, Candiolo, Italy)

Phosphopeptide-specific TCRs for cancer cell therapy and how to find them
Speaker: Eleni Chantzoura (AgenTus Therapeutics Ltd, Cambridge, United Kingdom)

Development of MyD88L265P mutation-specific TCR gene therapy for treatment of B-cell lymphoma and leukemia
Speaker: Özcan Çınar (Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany)

Nanobody based CD70 specific chimeric antigen receptors to target both solid and liquid malignancies
Speaker: Stijn De Munter (Ghent University, Gent, Belgium)

Highly multiplexed, single-cell functional profiling of CAR-T cells enables clinically predictive product characterization, cell manufacturing analysis, and cellular biomarkers across product types
Speaker: Peter Djali (IsoPlexis, Branford, United States)

A validated in vitro approach to preclinical safety and efficacy evaluation of human-specific ImmTAC® molecules in immunotherapy
Speaker: Tomasz Dobrzycki (Immunocore Ltd, Abingdon, United Kingdom)

Protransduzin™ - a novel transduction enhancer to accelerate en gros CAR-T production
Speaker: Michael Drosch (JPT Peptide Technologies GmbH, Berlin, Germany)

Engineering antigen-specific natural killer cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer
Speaker: Adil Doganay Duru (Nova Southeastern University, Davie, United States)

Cognate interaction with CD4+ T cells instructs tumor-associated macrophages to acquire M1-like phenotype
Speaker: David Eisel (German Cancer Research Center, Heidelberg, Germany)

Intratumor adoptive transfer of IL-12 mRNA transiently engineered anti-tumor CD8+ T cells
Speaker: Iñaki Etxeberria (Center for Applied Medical Research (CIMA), Pamplona, Spain)

Selecting CD8-specific DARPinS improves T lymphocyte-directed gene delivery
Speaker: Annika Melanie Frank (Paul Ehrlich Institute, Langen, Germany)
Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression
Speaker: Ioannis Gavvovidis (T-Knife GmbH, Berlin, Germany)

Shaping functional avidity of CAR-T cells: affinity, avidity and antigen density that lead to optimized response
Speaker: Raanan Greenman (Technion, Haifa, Israel)

Clinical-scale and GMP-compliant production of CAR-T cells for the treatment of melanoma patients by mRNA transfection of a CSPG4-specific chimeric antigen receptor
Speaker: Stefanie Gross (Universitätsklinikum Erlangen, Erlangen, Germany)

Effective HLA-independent adoptive immunotherapy in a three-dimensional (3D) melanoma model
Speaker: Ilenia Iaia (University of Turin, Department of Oncology, Candiolo, Italy)

Targeted knock-in of an HLA-independent, TRP2-specific chimerized TCR using CRISPR/Cas9 and rAAV6
Speaker: Korbinian Kropp (University Cancer Center (UCT), Research Center for Immunotherapy (FZI), University Medical Center (UMC) of the Johannes Gutenberg University and German Cancer Consortium (DKTK), Internal Medicine III, Mainz, Germany)

PD-L1-specific immunocytokines augment functionality and antitumor activity of CAR-engineered NK cells
Speaker: Aline Lindner (Georg-Speyer-Haus, Frankfurt am Main, Germany)

Generation of cord blood TCRαβ-/-CD8+ T-cells expressing recombinant WT1126-TCR to decrease relapse in acute myeloid leukemia pediatric patients after cord blood transplantation
Speaker: Vania Lo Presti (UMC-Utrecht, Utrecht, Netherlands)

A safe and highly active NY-ESO-1/LAGE-1-specific TCR for adoptive T cell therapy of cancer
Speaker: Giulia Longinotti (Medigene Immunotherapies GmbH, Planegg-Martinsried, Germany)

Neoantigen-specific CD8 T cells are structurally and functionally overlapping with CD8 T cells recognizing shared self-tumor and viral epitopes
Speaker: Morgane Magnin (Lausanne University Hospital Centre (CHUV), Epalinges, Switzerland)

NK cells specifically TCR-dressed to kill cancer cells
Speaker: Nadia Mensali (Oslo University Hospital Radiumhospitalet, Oslo, Norway)

CAR-T cell therapy: Investigating clinical challenges using a modelling & simulation framework
Speaker: Anna Mueller-Schoell (Freie Universität Berlin, Berlin, Germany)

Flow cytometric assays with automated data acquisition and analysis for CAR T cell manufacturing and patient immunomonitoring
Speaker: Marsilius Mues (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)

Human V61+ T cells: a potential tool for allogeneic adoptive cell therapy with innate, antigen independent tumour recognition potential
Speaker: Oliver Nussbaumer (GammaDelta Therapeutics Ltd, London, United Kingdom)

Directed differentiation of mobilized HSCs into functional NK cells with enhanced antitumor activity
Speaker: Pranav Oberoi (Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany)

Establishment of a novel T-cell-based scFv screening technology to advance modified antibody-based immunotherapy
Speaker: Toshiki Ochi (Ehime University Graduate School of Medicine, Toon, Japan)

Sequential two-receptor priming CAR system to overcome heterogeneous antigen expression in glioblastoma
Speaker: Hideho Okada (University of California San Francisco, San Francisco, United States)

A novel in vitro screening method unravels targets for NK cell-based cancer immunotherapy
Speaker: Didem Ozkazanc-Unsal (Sabanci University, Istanbul, Turkey)
ACTallo®: using allogeneic gamma-delta T cells to treat cancer  
Speaker: Nina Pawlowski (Immatics Biotechnologies GmbH, Tübingen, Germany)

PD-L1 and IL-1α combination on artificial antigen-presenting scaffold yield expansion of 
antigen-specific CD8 T cells with a multifunctional profile  
Speaker: Vibeke Mindahl Rafa (Technical University of Denmark, Kgs Lyngby, Denmark)

Smac mimetic (SM) induced sensitization of rhabdomyosarcoma (RMS) cells towards natural 
killer (NK) cell mediated killing  
Speaker: Lisa Marie Reindl (University Hospital Frankfurt, Frankfurt, Germany)

Liquidation of solid tumors by in vivo expanded CLDN6-CAR T cells  
Speaker: Katharina Reinhard (BioNTech Cell & Gene Therapies GmbH, Mainz, Germany)

Rapid and efficient generation of chimerized αβTCR constructs by seamless cloning of CDR1, 
2 and 3 hypervariable domains into a universal vector backbone  
Speaker: Tim J. Schäufele (University Cancer Center (UCT), Research Center for Immunotherapy (FZI), 
University Medical Center (UMC) of the Johannes Gutenberg University and German Cancer Consortium 
(DKTK), Internal Medicine III, Mainz, Germany)

TCR-pMHC 2D affinity is a robust predictor of adoptive CD8+ T cell transfer therapy efficacy 
in vivo  
Speaker: Julien Schmidt (University of Lausanne, Epalinges, Switzerland)

HD-CAR-1 clinical trial for employing CD19+ lymphoid neoplasias 3rd generation CART cells  
Speaker: Michael Schmitt (University Hospital Heidelberg, Heidelberg, Germany)

Reducing necessity of cmv specific T cell therapy: real-world data on leterminovir prophylaxis 
for cmv reactivation after allogeneic hematopoietic cell transplantation  
Speaker: Michael Schmitt (University Hospital Heidelberg, Heidelberg, Germany)

Establishment of a single copy gene-based qPCR for vector copy number determination in 
CART T cells as safety release criterion in GMP-manufacturing and for screening post 
treatment  
Speaker: Michael Schmitt (University Hospital Heidelberg, Heidelberg, Germany)

Point-of-care production of CD19 CAR-T cells in an automated closed-system; single center 
experience  
Speaker: Larisa Shelikhova (‘Dmitry Rogachev National Medical Research Centre for Pediatric 
Hematology, Oncology and Immunology’, Moscow, Russian Federation)

GMP-compliant flow cytometric cell sorting of antigen-specific T cells using MACS® GMP 
CD8-APC and MACS® GMP CD137-PE Fluorescent Antibodies on the MACSQuant® Tyto® 
Sorter  
Speaker: Christiane Siewert (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)

The expansion and survival of CAR T cells is enhanced by IL-21 through inhibition of their 
terminal differentiation following recognition of tumor target cells  
Speaker: Martin Štach (Institute of Hematology and Blood Transfusion, Prague, Czech Republic)

Highly efficient non-cytotoxic transduction enhancer - LentiBOOSTTM for pre-clinical 
research and clinical manufacturing of CD34+ cells using Lentiviral vectors  
Speaker: Cristina I. Ureche (SIRION Biotech GmbH, Planegg, Germany)

Vapor nanobubble photoporation as a new, safe and efficient technique for the delivery of 
small interfering RNA to lymphocyte cells  
Speaker: Jelter Van Hoeck (Ghent University and VIB, Ghent, Belgium)

Improvement of CD19 CAR target restriction through combinatorial design  
Speaker: Sébastien Wälchli (Oslo University Hospital, Oslo, Norway)

Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells 
bearing dead tumor antigen  
Speaker: Stefanie K Wculek (Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 
Spain)
A precision medicine-directed umbrella trial design of two first-in-human solid tumor CAR-T products in subjects with recurrent or refractory stage IV mRCC
Speaker: Tongyu Zhu (Fudan University, Shanghai Public Health Clinical Center, Shanghai, China)

Poster Session
15:00 - 17:30
West Foyer

Poster Session - Therapeutic Vaccination

A pre-existing inflammatory immune microenvironment predicts the clinical response of vulvar high grade squamous intraepithelial lesion to HPV16 SLP vaccination
Speaker: Ziena Abdulrahman (Leiden University Medical Center, Leiden, Netherlands)

Targeting a Kras neoantigen peptide vaccine to DNGR-1+ dendritic cells
Speaker: Rachel Ambler (The Francis Crick Institute, London, United Kingdom)

TheraVision - platform technology for the development, production and testing of oncolytic viruses
Speaker: Susanne M. Bailer (Fraunhofer-Institute for Interfacial Engineering and Biotechnology IGB, Stuttgart, Germany)

Mass spectrometry driven deep exploration of tumor-rejecting neoepitopes in a mouse sarcoma reveals novel characteristics of neoepitope-driven anti-tumor immunogenicity
Speaker: Michal Bassani-Sternberg (UNIL/CHUV, Epalinges, Switzerland)

Reinforcing dendritic cells for cancer immunotherapy: diverse ways to target antigens to human skin
Speaker: Lydia Bellmann (Medical University of Innsbruck, Innsbruck, Austria)

VEGF based active immunotherapy rescue tumor microenvironment from the immune suppression induced by heterotopic CT26 colon carcinoma challenge
Speaker: Monica Bequet-Romero (Center for Genetic Engineering and Biotechnology, Havana, Cuba)

The HLA-presented peptidome of healthy human organs: possible implications for immunotherapy
Speaker: Leon Bichmann (University Tübingen, Tübingen, Germany)

Evaluation of MHC class-I binding prediction tools: performance assessment and threshold recommendations based on experimentally validated ligands
Speaker: Maria Bonsack (German Cancer Research Center (DKFZ), Heidelberg, Germany)

HEPAVAC-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma
Speaker: Luigi Buonaguro (Istituto Nazionale Tumori Pascale, Napoli, Italy)

Precision nanotechnology-based therapeutics to regulate tumor-immune cells crosstalk against melanoma
Speaker: Bárbara Carreira (University of Lisbon, Faculty of Pharmacy, Research Institute for Medicines (iMed.ULisboa), Lisboa, Portugal)

Immunogenic tumor cell lysates modulate coding and non-coding RNA profiles of dendritic cell vaccine based on immunogenic cell death
Speaker: Jessica Dal Col (University of Salerno, Baronissi, Italy)

Multidisciplinary T cell dendritic cell vaccine immune responses correlate with clinical response in TriMixDC-MEL IPI study, a study with TriMix/tumor antigen mRNA dendritic cells plus ipilimumab in patients with advanced melanoma
Speaker: Brenda De Keersmaecker (eTheRNA Immunotherapies NV, Niel, Belgium)

Development of a cancer vaccine strategy by tumor antigen targeting to CD169+ antigen presenting cells.
Speaker: Joke den Haan (Amsterdam UMC, VUMC, Amsterdam, Netherlands)
XS15: an innovative lipopeptide adjuvant for peptide vaccination. Development of GMP-conform quality control analysis in RP-HPLC systems
Speaker: Marion Gauger (University of Tübingen, Interfaculty Institute for Cell Biology, Tübingen, Germany)

Pave the way for industry: validation of the LC-MS/MS immunopeptidomics method for the identification of HLA-restricted peptides suitable for pharmaceutical therapies according to the current US food and drug administration and European medicines agency guidelines
Speaker: Michael Ghosh (University of Tübingen, Tübingen, Germany)

A phase I/II vaccine clinical trial in metastatic malignant melanoma patients with step by step optimized mRNA-electroporated dendritic cells: an increase in survival correlates with eosinophilia and upregulation of PEBP1
Speaker: Stefanie Gross (Universitätsklinikum Erlangen, Erlangen, Germany)

Dendritic cell vaccination of a type III gastric neuroendocrine tumor and a microsatellite-stable colorectal carcinoma patient: immunological and clinical responses
Speaker: Stefanie Gross (Universitätsklinikum Erlangen, Erlangen, Germany)

Evaluating maturation cocktails for activation of blood dendritic cells: one does not fit all
Speaker: Gerulf Häanel (University Hospital, LMU Munich, Munich, Germany)

Mutatome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)
Speaker: Ludwig Heessen (BioNTech AG, Mainz, Germany)

A novel cancer immunotherapy combines rMVA-CD40L with tumor targeting antibodies
Speaker: Maria Hinterberger (Bavarian Nordic, Planegg, Germany)

MIDRIXNEO, taking personalized medicine to the next level
Speaker: Joline Ingels (University of Ghent, Ghent, Belgium)

Safety and therapeutic profile of a GnRH based vaccine candidate directed to prostate Cancer. A ten year follow-up of patients vaccinated with Heberprovac
Speaker: Jesús Arturo Junco Barranco (Center for Genetic Engineering and Biotechnology of Camaguey, Camaguey, Cuba)

PrDx a novel stability-based MHC/epitope prediction tool trained on data from the Neoscreen platform, and presentation of a first case where NeoScreen was applied for the selection of 40 neo-epitopes amongst 20000 mutations in a colorectal cancer patient
Speaker: Sune Justesen (Immunitrack, Copenhagen, Denmark)

Dexamethasone pre-medication suppresses cancer vaccine-induced T cell immunity
Speaker: Lena Kranz (BioNTech Corporation, Mainz, Germany)

Site-specific AAV2 modification for retargeting to tumor tissue
Speaker: Juliane Kuklik (Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach Riß, Germany)

Identification and immunological characterization of HLA-A3-restricted epitopes derived from HPV16 E6 and E7
Speaker: Catharina Lotsch (German Cancer Research Center (DKFZ), Heidelberg, Germany)

Ligandome analysis of AT/RTs reveals suitable targets for brain tumor immunotherapy
Speaker: Ana Marcu (University of Tübingen, Tübingen, Germany)

An innovative combined immunization platform for personalized cancer immunotherapy
Speaker: Jessica Matta (Odimmma SAS, Matzenheim, France)

Nanodisc platform technology for cancer vaccination
Speaker: James Moon (University of Michigan, Ann Arbor, United States)

High-throughput kinetic screenings of T cell engaging receptors with peptide-receptive HLA-A*02:01 molecules
Speaker: Andreas Moritz (Immetrics biotechnologies, Tübingen, Germany)
Multivalent polypeptide-based nanovaccine as anti-cancer immunotherapeutic strategy for melanoma
Speaker: Liane Moura (University of Lisbon, Faculty of Pharmacy, Research Institute for Medicines, Lisbon, Portugal)

Cellular and molecular changes in the anti-tumor immune response after therapeutic vaccination with CpG and αGC
Speaker: Lisa Charlotte Norkus (University Hospital Bonn, Institute of Experimental Immunology, Bonn, Germany)

Discovery of tumor antigens for triple-negative breast cancer and their in vivo immunogenicity and tumor control potential
Speaker: Karita Peltonen (University of Helsinki, Helsinki, Finland)

PeptiCRAd - a novel oncolytic virus based therapeutic cancer vaccine for the treatment of solid tumors
Speaker: Sari Pesonen (Valo Therapeutics, Helsinki, Finland)

IVAC-ALL-1: Interim analysis of a phase I/II clinical study on personalized peptide vaccination based on patient-individual tumor-specific variants in relapsed pediatric acute lymphoblastic leukemia
Speaker: Armin Rabsteyn (University Children's Hospital Tübingen, Tübingen, Germany)

Boron nitride nanotubes as potent peptide carrier to improve the efficiency of therapeutic anticancer vaccines
Speaker: Laurie Rangan (University Bourgogne Franche-Comté, INSERM, EFS BFC, Besançon, France)

Modeling immunogenicity with omics data integration
Speaker: Thomas Rösler (TRON - Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH, Mainz, Germany)

Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment
Speaker: Annika Rössler (Medical University of Innsbruck, Innsbruck, Austria)

Type I IFN responsiveness of melanoma is cell state dependent and can be both harnessed and suppressed to enhance oncolytic virotherapy efficacy
Speaker: Janne Ruotsalainen (University Hospital Magdeburg, Magdeburg, Germany)

Multifunctional antibody construct for in vivo targeting of dendritic cells as a therapeutic vaccination strategy in AML
Speaker: Saskia Schmitt (Gene Center of the LMU Munich, Munich, Germany)

E6/E7 RNA(LIP): An RNA cancer vaccine for treatment of patients with HPV16-positive malignancies
Speaker: J. Setzer (Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz, Germany)

WT1 oral cancer vaccine combined with anti-PD-1 antibody completely suppressed tumor growth in a murine bladder cancer model
Speaker: Toshiro Shirakawa (Kobe University Graduate School of Science, Technology and Innovation, Kobe, Japan)

An in vitro study of the interactions between the cell based cancer vaccine DCP-001 and antigen presenting cells
Speaker: Satwinder Kaur Singh (DCprime bv, Leiden, Netherlands)

This abstract has been withdrawn

Rescue of skin dendritic cells is key for the resuscitation of the anti-tumor immune responses in melanoma
Speaker: Patrizia Stoitzner (Medical University Innsbruck, Innsbruck, Austria)

A first in man phase I/II adjuvant dendritic cell vaccine study in high-risk prostate cancer patients following radical surgery reduce the incidence of biochemical relapse
Speaker: Anne Merete Aa. Tryggestad (Oslo University Hospital, Radiooncology, Oslo, Norway)

Tumor microenvironment signature after oncolytic VSV-GP therapy
Speaker: Carles R. Urbiola (Medical University Innsbruck, Innsbruck, Austria)
Multimodal immunotherapy for patients with ovarian cancer
Speaker: Stefaan Van Gool (IOZK, Köln, Germany)

V3: Tentacle-based ion exchange resins for viral vaccines, virus-like particles, and viral vector purification
Speaker: Elena Wüstenhagen (Merck KGaA, Darmstadt, Germany)

Establishment of an orthotopic HPV16 tumor model in MHC-humanized mice
Speaker: Samantha Zottnick (Immunotherapy and Immunoprevention, German Cancer Research Center (DKFZ), Heidelberg, Germany)

Plenary Session
17:30 - 18:30
Gutenberg Hall

Keynote Lecture
Chair: Özlem Türeci (BioNTech AG, Mainz, Germany)

Tools for T cells: Specificity and function in autoimmunity, infectious diseases and cancer
Speaker: Mark Davis (Stanford University, Stanford, United States)

CIMT Award Ceremony
18:30 - 19:30
Gutenberg Hall

CIMT Lifetime Achievement Award
Chair: Christoph Huber (CIMT, Mainz, Germany)

Ludwig van Beethoven: Variations on a theme from Mozart’s “Magic flute”: “Bei Männern, welche Liebe fühlen”
Speaker: Christoph Huber (CIMT, Mainz, Germany)

Laudatory speech
Speaker: Christoph Huber (CIMT, Mainz, Germany)

Acceptance speech
Speaker: Wolf H. Fridman (University Paris-Descartes, Paris, France)

Jules Massenet: “On dit”

Hector Berlioz: “La Captive”
**Wednesday, 22 May 2019**

### Immunoguiding

**Chair:** Sine Reker Hadrup (Technical University of Denmark, Copenhagen, Denmark)  
**Chair:** Marij J.P. Welters (Leiden University Medical Center, Leiden, Netherlands)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:30</td>
<td>Profiling antigen-specific T cells to understand diversity in the tumor-specific immune response</td>
<td>Evan Newell (Fred Hutchinson Cancer Research Center, Seattle, United States)</td>
<td>Gutenberg Hall</td>
</tr>
<tr>
<td>08:30 - 09:00</td>
<td>NKG2A as a novel checkpoint on CD8 T cells</td>
<td>Thorbald van Hall (Leiden University Medical Center, Leiden, Netherlands)</td>
<td>Gutenberg Hall</td>
</tr>
<tr>
<td>09:00 - 09:30</td>
<td>Decoding T cell (cross)reactivity for therapeutic interventions.</td>
<td>Jan Kisielow (ETC Zurich, Zurich, Switzerland)</td>
<td>Gutenberg Hall</td>
</tr>
</tbody>
</table>

### Coffee Break

09:30 - 10:00  
Exhibition Hall

### Tumor Microenvironment

**Chair:** Cornelis Melief (ISA Pharmaceuticals, Leiden, Netherlands)  
**Chair:** Wolf H. Fridman (University Paris-Descartes, Paris, France)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 - 10:30</td>
<td>Dissecting immune complexity of metastatic breast cancer</td>
<td>Karin de Visser (Netherlands Cancer Institute, Amsterdam, Netherlands)</td>
<td>Gutenberg Hall</td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>Deciphering T cell evolution in non-small cell lung cancer</td>
<td>Sergio A. Quezada (University College London, London, United Kingdom)</td>
<td>Gutenberg Hall</td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td>Redirecting T-cells for cancer immunotherapy using next generation bispecific antibodies and fusion proteins</td>
<td>Pablo Umana (Roche, Schlieren, Switzerland)</td>
<td>Gutenberg Hall</td>
</tr>
</tbody>
</table>

### Lunch Break

11:30 - 13:30  
Exhibition Hall

### Corporate Supported Symposium

**Immuno-oncology 2019 and beyond supported by Bristol-Myers Squibb**

**Chair:** Dirk Jäger (National Center for Tumor Diseases, Heidelberg, Germany)
New approaches to overcome IO resistance
Speaker: Angela Krackhardt (Technical University Munich, Munich, Germany)

12:00 - 12:30

Precision Medicine in IO: what’s new and what’s next?
Speaker: Wilfried Roth (University Medical Center Mainz, Mainz, Germany)

12:30 - 13:00

Plenary Session
13:30 - 15:00
Gutenberg Hall

Improving Immunity supported by HI-TRON Mainz Helmholtz Institute for Translational Oncology
Chair: Özlem Türeci (BioNTech AG, Mainz, Germany)
Chair: Borhane Guezguez (German Cancer Research Center DKFZ, Heidelberg, Germany)

Neutralizing TNF-apha and IL-8 to make the most of checkpoint blockade
Speaker: Ignacio Melero (Clinica Universidad de Navarra, Pamplona, Spain)

13:30 - 14:00

Individualized cancer immunotherapy: Targeting neo-antigens and beyond
Speaker: Ugur Sahin (TRON, BioNTech, Mainz, Germany)

14:00 - 14:30

How to individualize immunotherapy?
Speaker: Dirk Jäger (National Center for Tumor Diseases, Heidelberg, Germany)

14:30 - 15:00

Plenary Session
15:00 - 15:30
Gutenberg Hall

VOP, Voice of the Patient
Chair: Özlem Türeci (BioNTech AG, Mainz, Germany)

A patient’s story
Speaker: Ali Afghan (Hillsboro, United States)

15:00 - 15:30

Coffee Break
15:30 - 16:00
Exhibition Hall

Coffee Break

Poster Session
15:30 - 18:00
Exhibition Hall

Poster Session - New Targets & New Leads

Catch the right TCR - TCR discovery for Immatics’ immunotherapeutic applications
Speaker: Leonie Alten (Immatics Biotechnologies GmbH, Tuebingen, Germany)

Mass spectrometric analysis delineates upregulation of HLA-presented cancer/testis antigens in acute myeloid leukemia under decitabine treatment
Speaker: Jens Bauer (University of Tübingen, Tübingen, Germany)

Immunopeptidome analysis of multiple myeloma identifies a naturally presented BCMA-derived peptide as an immunogenic T-cell epitope for immunotherapy
Speaker: Tatjana Bilich (University of Tübingen, Institute for Cell Biology, Tübingen, Germany)
Comprehensive genomic and transcriptomic analysis of primary and recurrent/metastatic head and neck cancers
Speaker: Luisa Bresadola (TRON - Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany)

HLA class I peptidome analysis delineates naturally presented differentiation antigens for prostate carcinoma immunotherapy
Speaker: Lena Katharina Freudenmann (University of Tübingen, Interfaculty Institute for Cell Biology, Tübingen, Germany)

Development of PAC-1 single agent and combination therapies to treat multiple cancers
Speaker: Marlies Hager (University of Illinois at Urbana-Champaign, Urbana, United States)

Tumor infiltrating T cells from clear cell renal cell carcinoma patients recognize neopeptides derived from point and frameshift mutations
Speaker: Ulla Kring Hansen (Technical University of Denmark, National Veterinary Institute, Lyngby, Denmark)

Analysis of antibody responses against tumor-associated antigens in TNBC
Speaker: Anne-Sophie Heimes (University Medical Center of Johannes Gutenberg-University Mainz, Mainz, Germany)

A novel antagonistic CD73 antibody for cancer immunotherapy
Speaker: Irmgard Hofmann (Boehringer Ingelhein RCV GmbH & Co KG, Vienna, Austria)

Local immunotherapy with a mixture of cytokine-encoding mRNAs promotes potent anti-tumor immunity and tumor eradication
Speaker: Christian Hotz (BioNTech Corporation, Mainz, Germany)

CRISPR screening in primary human immune cells
Speaker: Daniela Hueber (Horizon Discovery Ltd, Cambridge, United Kingdom)

AT1413 antibody derived from a cured AML patient recognizes a unique CD43 epitope shared by AML, MDS and melanoma cells
Speaker: Martijn Kedde (AIMM Therapeutics, Amsterdam, Netherlands)

Development of highly potent bispecific T-Cell engaging receptors (TCER®) targeting tumor-specific HLA ligands
Speaker: Katharina Kiesel (Immmatics Biotechnologies GmbH, Tübingen, Germany)

Factors other than HLA-I expression and mutational load can influence neoantigen identification through immunopeptidomics
Speaker: Maria Lozano-Rabella (Vall d’Hebron Institute of Oncology (V.H.I.O.), Barcelona, Spain)

Genome wide screens in vivo identify SOCS-1 a dominant intrinsic checkpoint of CD4 T cells quorum sensing
Speaker: Laurie Menger (Institute Curie, Paris, France)

Identification and characterization of the HLA ligandomic landscape for immunotherapeutic approaches in oropharyngeal squamous cell carcinoma
Speaker: Lena Mühlenbruch (University of Tübingen, Tübingen, Germany)

Identification of naturally presented HLA ligands of CD34+CD38- acute myeloid leukemia (AML) progenitor cells for T cell-based immunotherapy - neoeptopes and self-peptides as novel targets for anti-cancer therapy
Speaker: Annika Nelde (University of Tübingen, Institute for Cell Biology, Tübingen, Germany)

Epigenetic control of CD8+ T cell exhaustion and responsiveness to a-PD-1 by Suv39h1
Speaker: Leticia L. Niborski (PSL Research University, Institute Curie, Translational Research Department, Paris, France)

Effects of MALAT1 modulation on cisplatin sensitivity in solid, viable human lung tumor tissue and co-cultures of A549 and fresh human lung slices
Speaker: Sabrina Osterhof (Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany)

Immune checkpoint inhibitor in nasopharyngeal carcinoma: off-label experience
Speaker: Jong Chul Park (Massachusetts General Hospital Cancer Center, Boston, United States)
Overview of immuno-oncology clinical trial conduct and design investigating combination therapies
Speaker: Inka Pawlitzky (SMS-Oncology, Schiphol, Netherlands)

Augmenting immunotherapy impact by lowering tumor TNF cytotoxicity threshold
Speaker: Daniel S. Peeper (Netherlands Cancer Institute, Amsterdam, Netherlands)

MACTech: a functional ex vivo platform for target identification and compound screening in macrophages
Speaker: Aurélien Pommier (University of Geneva, School of Pharmaceutical Sciences, Geneva, Switzerland)

HLA-C restricted neoepitopes contribute significantly to the immune recognition of cancer
Speaker: Sofie Ramskov (Technical University of Denmark, Kgs Lyngby, Denmark)

Identification of AR1 as a novel immune modulator in lung cancer using an RNA-i based high-throughput discovery platform
Speaker: Anchana Rathinasamy (Regensburg Center for Interventional Immunology (RCI), Regensburg, Germany)

Functional identification and therapeutic targeting of cancer neoantigens
Speaker: Stephen P. Schoenberger (La Jolla Institute, La Jolla, CA, United States)

A patient derived antibody targeting the tetraspanin CD9 synergistically inhibits tumor growth with an anti PD1 antibody
Speaker: Remko Schotte (AIMM Therapeutics, Amsterdam, Netherlands)

HERA-CD27L, a true CD27 agonist, has superior activity over benchmark agonistic antibodies and induces T cell activation for potent anti-tumor immunity
Speaker: Julian P. Sefrin (Apogenix AG, Heidelberg, Germany)

Direct detection of frameshift neoantigens candidates from whole genome sequencing
Speaker: Riccha Sethi (TRON gGmbH- Translational Oncology at Johannes Gutenberg-University Medical Center, Mainz, Germany)

A novel combination immunotherapy for pancreatic cancer: IL-15 and CD40 stimulation join hands to raise the stakes
Speaker: Jonas R. M. Van Audenaarde (University of Antwerp, Wilrijk, Belgium)
Speaker: Evelien Smits (University of Antwerp, Wilrijk, Belgium)

Exposing TNF receptor super family members as therapeutic targets for pancreatic cancer
Speaker: Tim Steinfatt (University Hospital Würzburg, Würzburg, Germany)

EBV transcript detection in gastric cancer using droplet digital PCR
Speaker: Marijana Slijepcevic (TRON - Translational Oncology at the University Medical Center of the Johannes Gutenberg University gGmbH, Mainz, Germany)
Speaker: Martin Suchan (TRON - Translational Oncology at the University Medical Center of the Johannes Gutenberg University gGmbH, Mainz, Germany)

Neoantigen load, tumor immune infiltration and prediction of survival in HCC patients
Speaker: Maria Tagliamonte (National Cancer Institute, Napoli, Italy)

Mitochondrial morphological and functional reprogramming following CD137 (4-1BB) costimulation
Speaker: Alvaro Teijeira (CIMA Universidad de Navarra, Pamplona, Spain)

A bispecific T cell engaging antibody binding CD3 and CD43s has strong anti-AML activity in vivo without affecting normal hematopoiesis
Speaker: Pauline M van Helden (AIMM Therapeutics, Amsterdam, Netherlands)

Identification of mutanome-encoded T-cell epitopes in PDAC on the basis of xenograft NGS data using a hybrid reference genome
Speaker: Michael Volkmar (German Cancer Research Center (DKFZ), Heidelberg, Germany)

A screening for novel immune-checkpoints identifies a serine/threonine kinase to trigger immune resistance of PD-L1 refractory tumor cells
Speaker: Valentina Volpin (Regensburg Center for Interventional Immunology (RCI), Regensburg, Germany)
Identification of immunogenic fusion genes in CT26 and B16-F10 mouse cell lines  
Speaker: David Weber (TRON–Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz gGmbH, Mainz, Germany)

The great escape: role of the actin cytoskeleton in cancer immune evasion  
Speaker: Hannah Wurzer (Luxembourg Institute of Health, Luxembourg, Luxembourg)

Poster Session
15:30 - 18:00  
Exhibition Hall

Poster Session - Improving Immunity

Computational strategy to modulate PD-1/PD-L1 interaction and activate T cells function through small molecules  
Speaker: Rita C. Acurcio (University of Lisbon, Faculty of Pharmacy, Research Institute for Medicines (iMed.ULisboa), Lisboa, Portugal)

Pro-immunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in T cell mediated tumor therapy  
Speaker: Daniel Baumann (German Cancer Research Center (DKFZ), Heidelberg, Germany)

Immune checkpoint blockade reverses obesity-associated defects in cancer immunosurveillance  
Speaker: Lydia Dyck (Trinity College Dublin, Dublin, Ireland)

IL-32 induces multiple arms of anti-tumor immunity in mouse models of cancer  
Speaker: Thomas Gruber (Universität Bern, Bern, Switzerland)

Photon versus carbon ion irradiation – impact on immune modulation and establishment of an abscopal breast cancer model  
Speaker: Laura Hartmann (German Cancer Research Center (DKFZ), Heidelberg, Germany)

Investigation of the synergistic effects of anti-YKL-40 therapy in combination with immunotherapy on the tumor microenvironment  
Speaker: Astrid Zedlitz Johansen (Herlev & Gentofte Hospital, Herlev, Denmark)

Dynamic changes in transcriptome and cytokine expression in melanoma patients treated with combination PD-1 and CTLA-4 inhibitors  
Speaker: Su Yin Lim (Macquarie University, Sydney, Australia)

Intratumoral RNA-based TLR-7/-8 and RIG-I agonist CV8102 alone and in combination with anti-PD-1 in a phase I dose-escalation and expansion trial in patients with advanced solid tumors  
Speaker: Michael Meister (CureVac AG, Tübingen, Germany)

Evaluation of combinatorial immunotherapeutic strategies for pancreatic cancer in an electroporation-based autochthonous mouse model  
Speaker: Julian Mochayedi (German Cancer Research Center (DKFZ), Heidelberg, Germany)

DuoBody-PD-L1x4-1BB combines checkpoint blockade and T-cell co-stimulation to promote anti-tumor immunity  
Speaker: Alexander Muik (BioNTech AG, Mainz, Germany)

In vivo live imaging of human T/B cell lymphoma cross-linking mediated by bispecific CD20-TCB antibody  
Speaker: Mario Perro (Roche Research and Early Development, Zurich, Switzerland)

IL2/anti-IL2 complex combined with CTLA-4, but not PD-1, blockade rescues antitumor NK cell function by regulatory T-cell modulation  
Speaker: Eliane Piaggio (Paris-Sciences-Lettres, Institut Curie Research Center, Paris, France)

HERA-CD40L, a hexavalent CD40 agonist, induces a significant T cell mediated anti-tumor immune response and shows superior activity in direct comparison to benchmark agonistic antibodies  
Speaker: David Richards (Apogenix AG, Heidelberg, Germany)
Highly superficial and replicable location of large volume single intradermal injection depots with dermaject® intradermal injection device compared to the Mantoux injection method  
Speaker: Sandra Schulz (Hahn-Schickard, Villingen-Schwenningen, Germany)

DuoBody-CD40x-4-1BB conditionally enhances immune activation by crosslinking CD40- and 4-1BB-expressing cells  
Speaker: Danita Schuurhuis (Genmab B.V., Utrecht, Netherlands)

Targeting the immunosuppressive tumor microenvironment and inducing immunogenic cell death with cold atmospheric plasma in pancreatic cancer  
Speaker: Evelien Smits (University of Antwerp, Wilrijk, Belgium)

Investigation of the immunomodulating effects of cold physical plasma for cancer therapy  
Speaker: Evelien Smits (University of Antwerp, Wilrijk, Belgium)

Lipid-storing, tumor-associated macrophages orchestrate a tumor-excluded immune landscape in omentum metastases of epithelial ovarian cancer  
Speaker: Meggy Suarez-Carmona (University Hospital Heidelberg, Heidelberg, Germany)

Exploring regulatory T cells as immunotherapy targets in ovarian cancer  
Speaker: Aras Toker (University Health Network, Toronto, Canada)
Characterization of syngeneic tumor models and their microenvironment for immunotherapeutic approaches  
Speaker: Marco Carretta (Herlev Hospital, Herlev, Denmark)

Bone marrow Aire-expressing plasma cells ectopically express tissue-restricted self-antigens and induce autoreactive regulatory T cells  
Speaker: Chih-Yeh Chen (Regensburg Center for Interventional Immunology (RCI), Regensburg, Germany)

Oncolysis is the predominant mechanism for the therapeutic effect of vesicular stomatitis virus variant VSV-GP in a mouse lung cancer model  
Speaker: Krishna Das (Medical University Innsbruck, Innsbruck, Austria)

A transcriptionally distinct CXCL13+CD103+CD8+ T-cell population is associated with B-cell recruitment and neoantigen load in human cancer  
Speaker: Marco de Bruyn (UMCG, Groningen, Netherlands)

High-dimensional cytometric analysis of colorectal cancer reveals novel and diverse mediators of anti-tumor immunity  
Speaker: Noel de Miranda (Leiden University Medical Center, Leiden, Netherlands)

Patient derived melanoma cells induce organ-specific immune responses in human lymph node tissue and PBMCs  
Speaker: Susann Dehmel (Fraunhofer ITEM, Hannover, Germany)

The prognostic significance of HLA-A*02 and HLA-A*24 in prostate cancer  
Speaker: Sotirios Fortis (Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece)

PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity  
Speaker: Maria Gato (FIMA, Pamplona, Spain)

Identification of prevalent immunomodulators for targeted immunotherapy in the sarcoma tumor microenvironment  
Speaker: Anna-Maria Georgoudaki (Karolinska Institutet, Huddinge, Sweden)

Deep deconvolution of HLA peptidomes for robust class I and class II epitope predictions  
Speaker: David Gfeller (University of Lausanne, Epalinges, Switzerland)

Imbalance between early and late differentiated intra-tumour CD4 T cells is associated with mutational burden and regulatory T cell abundance in non-small cell lung cancer  
Speaker: Ehsan Ghorani (UCL, London, United Kingdom)

MDSC and neutrophil recruitment and function in melanoma primary and metastatic lesions  
Speaker: Christopher Groth (Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany)

Single cell classification of cancerous tissue using multiplexed ion beam imaging (MIBI)  
Speaker: Ron Gulka (Ionpath, Inc, Menlo Park, United States)

Evaluation of MUC1 expression with the ultra high-content imaging platform MACSimaTM  
Speaker: Christoph Herbel (Miltenyi Biotec, Bergisch Gladbach, Germany)

Assessing the phylogenetic relationship of early cancer spread in melanoma as basis for neo-antigen identification for adjuvant immunotherapy  
Speaker: Sandra Huber (University of Regensburg, Regensburg, Germany)

Next-gen immune profiling using imaging mass cytometry as a framework for cancer immunotherapy  
Speaker: Marieke E. Ijsselsteijn (Leiden University Medical Center, Leiden, Netherlands)

Immunophenotyping treatment-naive head and neck cancers identify differential immune response in primary tumors and metastatic lymph nodes  
Speaker: N Gopalakrishna Iyer (National Cancer Centre, Singapore, Singapore)
Time-lapse proteomic analysis of urine during tumor development in a carcinogen induced bladder cancer model
Speaker: Iliana Kerzeli (Uppsala University, Uppsala, Sweden)

Characterization of the tumor microenvironment by unsupervised pattern recognition in multiparametric immunofluorescence images
Speaker: Jutta Kollet (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)

Interactions of patient-derived melanoma cells with tissue-resident macrophages and monocytes in fresh human lung tissue and human PBMC cultures
Speaker: Sebastian Konzok (Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany)

Intraepithelial CD4+ T cell count is predictive for better clinical outcome in vulvar cancer
Speaker: Kim E. Kortekaas (Leiden University Medical Center, Leiden, Netherlands)

Collagen density regulates the activity of tumor-infiltrating T cells
Speaker: Dorota Ewa Kuczek (Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev, Denmark)

Small cell lung cancer stem cells show adaptive resistance through effectively inducing T cell activation and modulating the expression of co-inhibitory receptors
Speaker: M. Alper Kursunel (Hacettepe University Cancer Institute, Ankara, Turkey)

Steroid hormones and immune infiltrates in adrenocortical carcinoma
Speaker: Laura-Sophie Landwehr (University Hospital Würzburg, Würzburg, Germany)

Collagen density modulates the immunosuppressive functions of tumor-associated macrophages
Speaker: Anne Mette Hvid Larsen (Center for Cancer Immune Therapy, Herlev Hospital, Herlev, Denmark)

The potential role of IL-19 in glioblastoma tumor microenvironment
Speaker: Gilbert Lee (Taipei Medical University Hospital, Taipei City, Taiwan, Republic of China)

Treatment outcome for primary cervix large B-cell lymphoma: a clinical analysis of 37 cases
Speaker: Xiaojian Liu (Fudan University, Cancer Hospital, Shanghai, China)

Identification of predictive biomarkers and therapeutic targets in urinary bladder cancer by high-sensitivity multiplex proximity extension assay
Speaker: Martin Lord (Uppsala University, Uppsala, Sweden)

The extracellular matrix protein collagen regulates immune activity within tumors
Speaker: Daniel Hargbøl Madsen (Copenhagen University Hospital Herlev, Center for Cancer Immune Therapy, Herlev, Denmark)

This abstract has been withdrawn

Investigation of the effect of hypoxia on presentation of HPV16-derived antigens
Speaker: Nitya Mohan (German Cancer Research Center (DKFZ), Heidelberg, Germany)

Study of mechanisms of immune evasion of oncogenic KRAS in NSCLC
Speaker: Edurne Mugarza (The Francis Crick Institute, London, United Kingdom)

Enhanced expression of CD47 contributes to off-target resistance to tyrosin kinase inhibitor gefitinib in NSCLC
Speaker: Annunziata Nigro (University of Salerno, Baronissi, Italy)

Cytokine profiling and identification of tumor infiltrating lymphocytes in different PDX models in humanized mice as potential classification of hot and cold tumors
Speaker: Eva Oswald (Charles River Discovery Research Services Germany, Freiburg, Germany)

Immunomodulatory effects of breast cancer-derived exosome mimic nanovesicles
Speaker: Mustafa Öztatlıci (Manisa Celal Bayar University, Manisa, Turkey)

Deep immune profiling of ovarian carcinoma patients during chemotherapy
Speaker: Sterre Paijens (University of Groningen, Groningen, Netherlands)
Characterizing naturally-occurring tumor-infiltrating lymphocyte (TIL) responses in endometrial cancer  
Speaker: Jara Palomero (Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain)

Xenoantigen dependent complement-mediated neutralization of LCMV glycoprotein pseudotyped VSV in human serum  
Speaker: Lisa Pipperger (Medical University of Innsbruck, Innsbruck, Austria)

Neoantigen burden and tumor immune escape define CD8 T cell dysfunction in primary NSCLC  
Speaker: James Luke Reading (University College London Cancer Institute, London, United Kingdom)

The novel hexavalent human GITR agonist HERA-GITRL promotes anti-tumor efficacy independent of Fc-functionality and shows superior activity compared with the monoclonal anti-GITR antibody TRX518  
Speaker: Matthias Schröder (Apogenix AG, Heidelberg, Germany)

Preclinical evaluation of novel anti-tumor immunotherapies using Hu-PBL humanized mouse model  
Speaker: Christine Sedlik (Institute Curie and PSL Research University, Paris, France)

Adenosine A2a receptor triggering labilizes cytotoxic T lymphocyte-target cell contacts and compromises tumor cell killing  
Speaker: Jeroen Slaats (Radboud University Medical Center, Nijmegen, Netherlands)

Establishment and characterization of unique murine bladder cancer cell lines from BBN-induced urothelial bladder carcinoma  
Speaker: Ivan Stepanek (Uppsala University, Uppsala, Sweden)

Intratumoral expression of HMGB1 controls the anticancer immune response  
Speaker: Betül Taşkoparan (University of Geneva, Geneva, Switzerland)

Investigating collagen-mediated suppression of tumor-infiltrating T cells in vivo  
Speaker: Marie-Louise Thorseth (Center for Cancer Immune Therapy, Herlev Hospital, Herlev, Denmark)

TCR rhapsody and single-cell RNA: tracing the mechanism of tumor-treg accumulation  
Speaker: Jimena Tosello (Institut Curie, Translational Research Department, Paris, France)

Characterization of circulating and tumor-infiltrating myeloid-derived suppressor cells in patients affected by pancreatic ductal adenocarcinoma  
Speaker: Rosalinda Trovato (University of Verona, Verona, Italy)

Assessment of neoantigen-specific CD8+ T cells in tumor-infiltrating lymphocytes expanded for adoptive T cell therapy in melanoma  
Speaker: Siri Amanda Tvingsholm (Technical University of Denmark, Kgs. Lyngby, Denmark)

Targeting lipid metabolism to improve cancer immunotherapy  
Speaker: Narasimha Rao Uda (University of Geneva, Geneva, Switzerland)

Neoantigen-specific T cell responses in low mutation burden colorectal cancers reveal immunotherapeutic potential  
Speaker: Jitske van den Bulk (LUMC, Leiden, Netherlands)

A non-functional neoepitope specific CD8+ T-cell response induced by tumor derived antigen exposure in vivo  
Speaker: Mathias Vormehr (Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz, Germany)

B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma  
Speaker: Johannes Griss (Medical University Vienna, Vienna, Austria)

Alterations in tumor microenvironment with high immune infiltration and expression of immunosuppressive molecules in recurrent tumor compared to matched primary tumor from ovarian cancer patients.  
Speaker: Marie Christine Wulff Westergaard (Center for Cancer Immune Therapy, Herlev, Denmark)
Cellular and cytokine profile characterization of Prostate Cancer Spheroids towards Docetaxel therapy resistance
Speaker: Kevin Woods (University Medical Center, Johannes Gutenberg University, Mainz, Germany)

Functional conversion of cytotoxic T cells into induced Treg in breast cancer patients
Speaker: Maria Xydia (Regensburg Center for Interventional Immunology (RCI), Regensburg, Germany)

A synthetic miR-193a-3p mimic (INT-1B3) suppresses primary tumor growth and prolongs animal survival by enhancing T-cell mediated immune response in murine TNBC 4T1 orthotopic model
Speaker: Sanaz Yahyanejad (InteRNA Technologies BV, Utrecht, Netherlands)

Rapid neoantigen-specific TCR discovery to dissect anti-tumoral mechanisms
Speaker: Ikra Yildiz (TRON gGmbH, Translational Oncology, Mainz, Germany)
Speaker: Shaheer Bardissi (BioNTech Cell and Gene Therapies, Mainz, Germany)

Recapitulating the orthotopic tumour microenvironment using bioluminescent syngeneic models in immune competent mice for checkpoint inhibitor interrogation
Speaker: Yinfei Yin (Crownbio Science UK, Loughborough, United Kingdom)

Evolution of HLA haplotype loss in melanoma patients and its association with resistance to immune checkpoint blockade
Speaker: Fang Zhao (University Hospital Essen, Essen, Germany)

Corporate Supported Symposium
18:00 - 19:00
Gutenberg Hall

Miltenyi Workshop
18:00 - 18:30
Cell therapy reloaded: from target discovery to cell manufacturing
Speaker: Caroline Blumer (Miltenyi Biotec, Bergisch Gladbach, Germany)

Live demo: CliniMACS Prodigy® T cell transduction process
Speaker: Michael Papadimitrious (Miltenyi Biotec, Bergisch Gladbach, Germany)

CIMT Social Event & Award Ceremony
20:00 - 23:59
KUZ-Kulturzentrum Mainz

CIMT Social Event & Poster Award Ceremony
Short Talk Session
08:30 - 10:00
Gutenberg Hall A

Therapeutic Vaccination
Chair: Sebastian Kreiter (TRON, Mainz, Germany)
Chair: Kris Thielemans (Vrije Universiteit Brussel, Brussels, Belgium)

WT1 oral cancer vaccine combined with anti-PD-1 antibody completely suppressed tumor growth in a murine bladder cancer model
Speaker: Toshiro Shirakawa (Kobe University Graduate School of Science, Technology and Innovation, Kobe, Japan) 08:30 - 08:45

A pre-existing inflammatory immune microenvironment predicts the clinical response of vulvar high grade squamous intraepithelial lesion to HPV16 SLP vaccination
Speaker: Ziena Abdulrahman (Leiden University Medical Center, Leiden, Netherlands) 08:45 - 09:00

Development of a cancer vaccine strategy by tumor antigen targeting to CD169+ antigen presenting cells.
Speaker: Joke den Haan (Amsterdam UMC, VUMC, Amsterdam, Netherlands) 09:00 - 09:15

Nanodisc platform technology for cancer vaccination
Speaker: James Moon (University of Michigan, Ann Arbor, United States) 09:15 - 09:30

Multivalent polypeptide-based nanovaccine as anti-cancer immunotherapeutic strategy for melanoma
Speaker: Liane Moura (University of Lisbon, Faculty of Pharmacy, Research Institute for Medicines, Lisbon, Portugal) 09:30 - 09:45

PeptiCRAd - a novel oncolytic virus based therapeutic cancer vaccine for the treatment of solid tumors
Speaker: Sari Pesonen (Valo Therapeutics, Helsinki, Finland) 09:45 - 10:00

Short Talk Session
08:30 - 10:00
Gutenberg Hall B

Cellular Therapy
Chair: Isabel Poschke (German Cancer Research Center DKFZ, Heidelberg, Germany)
Chair: Cedrik M. Britten (GlaxoSmithKline, Stevenage, United Kingdom)

Dissecting the T cell receptor interactions governing recognition of peptide-MHC complexes
Speaker: Amalie Kai Bentzen (Technical University of Denmark, Lyngby, Denmark) 08:30 - 08:45

Phosphopeptide-specific TCRs for cancer cell therapy and how to find them
Speaker: Eleni Chantzoura (AgenTus Therapeutics Ltd, Cambridge, United Kingdom) 08:45 - 09:00

Targeted knock-in of an HLA-independent, TRP2-specific chimerized TCR using CRISPR/Cas9 and rAAV6
Speaker: Korbinian Kropp (University Cancer Center (UCT), Research Center for Immunotherapy (FZI), University Medical Center (UMC) of the Johannes Gutenberg University and German Cancer Consortium (DKTK), Internal Medicine III, Mainz, Germany) 09:00 - 09:15
**Neoantigen-specific CD8 T cells are structurally and functionally overlapping with CD8 T cells recognizing shared self-tumor and viral epitopes**

Speaker: Morgane Magnin (Lausanne University Hospital Centre (CHUV), Epalinges, Switzerland)

09:15 - 09:30

**Human Vδ1+ T cells: a potential tool for allogeneic adoptive cell therapy with innate, antigen independent tumour recognition potential**

Speaker: Oliver Nussbaumer (GammaDelta Therapeutics Ltd, London, United Kingdom)

09:30 - 09:45

**Liquidation of solid tumors by in vivo expanded CLDN6-CAR T cells**

Speaker: Katharina Reinhard (BioNTech Cell & Gene Therapies GmbH, Mainz, Germany)

09:45 - 10:00

---

**Tumor Biology & Interaction with the Immune System**

Chair: Sergio A. Quezada (University College London, London, United Kingdom)

Chair: Tobias Bopp (University Medical Center Mainz, Mainz, Germany)

**Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer**

Speaker: Edith Borcoman (INSERM U932, Institut Curie, PSL University, Paris, France)

08:30 - 08:45

**Imbalance between early and late differentiated intra-tumour CD4 T cells is associated with mutational burden and regulatory T cell abundance in non-small cell lung cancer**

Speaker: Ehsan Ghorani (UCL, London, United Kingdom)

08:45 - 09:00

**Neoantigen-specific T cell responses in low mutation burden colorectal cancers reveal immunotherapeutic potential**

Speaker: Jitske van den Bulk (LUMC, Leiden, Netherlands)

09:00 - 09:15

**B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma**

Speaker: Johannes Griss (Medical University Vienna, Vienna, Austria)

09:15 - 09:30

**Functional conversion of cytotoxic T cells into induced Treg in breast cancer patients**

Speaker: Maria Xydia (Regensburg Center for Interventional Immunology (RCI), Regensburg, Germany)

09:30 - 09:45

**A synthetic miR-193a-3p mimic (INT-1B3) suppresses primary tumor growth and prolongs animal survival by enhancing T-cell mediated immune response in murine TNBC 4T1 orthotopic model**

Speaker: Sanaz Yahyanejad (InteRNA Technologies BV, Utrecht, Netherlands)

09:45 - 09:55

---

Coffee Break

10:00 - 10:30

Exhibition Hall
Actively personalized immunotherapies (by CIMT Regulatory Research Group)

Chair: Harpreet Singh (Immatics Biotechnologies, Tübingen, Germany)
Chair: Thomas Hinz (Paul-Ehrlich-Institut, Langen, Germany)

**Introduction and brief report on CIMT-RRG**
Speaker: Harpreet Singh (Immatics Biotechnologies, Tübingen, Germany)  
10:30 - 10:45

**Development and regulation of personalized immunotherapy products**
Speaker: Klaus Cichutek (Paul-Ehrlich-Institut, Langen, Germany)  
10:45 - 11:15

**Clinical development of glioma-directed (peptide) vaccines**
Speaker: Wolfgang Wick (Heidelberg University Hospital, Heidelberg, Germany)  
11:15 - 11:40

**Endogenous T cell therapies for precision medicine**
Speaker: Cassian Yee (MD Anderson Cancer Center, Houston, United States)  
11:40 - 12:05

**Matching future needs for world patient populations needing TCR-T therapies with different antigen specificities and HLA restrictions**
Speaker: Dolores Schendel (Medigene, Planegg, Germany)  
12:05 - 12:30

**US regulatory considerations for personalized immunotherapies**
Speaker: Peter Bross (FDA, CBER, Bethesda, United States)  
12:30 - 13:00

New Targets & New Leads

Chair: John Castle (Agenus Inc, Lexington, United States)
Chair: Stefan Stevanovic (University of Tübingen, Tübingen, Germany)

**Local immunotherapy with a mixture of cytokine-encoding mRNAs promotes potent anti-tumor immunity and tumor eradication**
Speaker: Christian Hotz (BioNTech Corporation, Mainz, Germany)  
10:30 - 10:45

**Genome wide screens in vivo identify SOCS-1 a dominant intrinsic checkpoint of CD4 T cells quorum sensing**
Speaker: Laurie Menger (Institute Curie, Paris, France)  
10:45 - 11:00

**Functional identification and therapeutic targeting of cancer neoantigens**
Speaker: Stephen P. Schoenberger (La Jolla Institute, La Jolla, CA, United States)  
11:00 - 11:15

**A bispecific T cell engaging antibody binding CD3 and CD43s has strong anti-AML activity in vivo without affecting normal hematopoiesis**
Speaker: Pauline M van Helden (AIMM Therapeutics, Amsterdam, Netherlands)  
11:15 - 11:30

**A screening for novel immune-checkpoints identifies a serine/threonine kinase to trigger immune resistance of PD-L1 refractory tumor cells**
Speaker: Valentina Volpin (Regensburg Center for Interventional Immunology (RCI), Regensburg, Germany)  
11:30 - 11:45

Improving Immunity

Chair: Thorbald van Hall (Leiden University Medical Center, Leiden, Netherlands)
Chair: Graham Pawelec (University of Tübingen, Tübingen, Germany)
Pro-immunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in T cell mediated tumor therapy
Speaker: Daniel Baumann (German Cancer Research Center (DKFZ), Heidelberg, Germany)

IL2/anti-IL2 complex combined with CTLA-4, but not PD-1, blockade rescues antitumor NK cell function by regulatory T-cell modulation
Speaker: Eliane Piaggio (Paris-Sciences-Lettres, Institut Curie Research Center, Paris, France)

HERA-CD40L, a hexavalent CD40 agonist, induces a significant T cell mediated anti-tumor immune response and shows superior activity in direct comparison to benchmark agonistic antibodies
Speaker: David Richards (Apogenix AG, Heidelberg, Germany)

Lipid-storing, tumor-associated macrophages orchestrate a tumor-excluded immune landscape in omentum metastases of epithelial ovarian cancer
Speaker: Meggy Suarez-Carmona (University Hospital Heidelberg, Heidelberg, Germany)

Exploring regulatory T cells as immunotherapy targets in ovarian cancer
Speaker: Aras Toker (University Health Network, Toronto, Canada)

Short Talk Session
Gutenberg Hall B
11:45 - 13:00

Immunomonitoring
Chair: Cecile Gouttefangeas (University of Tübingen, Tübingen, Germany)
Chair: Nadine Pronk van Montfoort (Leiden University Medical Center, Leiden, Netherlands)

Polymorphic T cell responses against a shared clonal driver mutation in astrocytoma
Speaker: Lukas Bunse (German Cancer Research Center (DKFZ), Heidelberg, Germany)

Immunotoxicity assessment in a circulating human whole blood system
Speaker: Erika Fletcher (Immuned AB, Uppsala, Sweden)

Skin adverse events during immune checkpoint inhibitor treatments correlate with frequency of tumor somatic mutations in skin-enriched genes
Speaker: Omar Hasan Ali (University Hospital Zurich, Zurich, Switzerland)

Prediction of irAEs in Ipilimumab-treated melanoma patients based on serum autoantibodies
Speaker: Jessica Hassel (University Hospital Heidelberg, Heidelberg, Germany)

Cellular Immunomonitoring for the personalized adoptive cellular therapy trial ACTolog® IMA101-101
Speaker: Anna Nowak (Immatics Biotechnologies GmbH, Tübingen, Germany)

Short Talk Session
North Foyer Hall
11:45 - 13:00

Clinical Trials
Chair: Özlem Türeci (BioNTech AG, Mainz, Germany)
Chair: Stephan Grabbe (University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany)

HEPAVAC-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma
Speaker: Luigi Buonaguro (Istituto Nazionale Tumori Pascale, Napoli, Italy)
Multiclonal T cell dendritic cell vaccine immune responses correlate with clinical response in TriMixDC-MEL IPI study, a study with TriMix/tumor antigen mRNA dendritic cells plus ipilimumab in patients with advanced melanoma
Speaker: Brenda De Keersmaecker (eTheRNA Immunotherapies NV, Niel, Belgium)

A phase I/II vaccine clinical trial in metastatic malignant melanoma patients with step by step optimized mRNA-electroporated dendritic cells: an increase in survival correlates with eosinophilia and upregulation of PEBP1
Speaker: Stefanie Gross (Universitätsklinikum Erlangen, Erlangen, Germany)

IVAC-ALL-1: Interim analysis of a phase I/II clinical study on personalized peptide vaccination based on patient-individual tumor-specific variants in relapsed pediatric acute lymphoblastic leukemia
Speaker: Armin Rabsteyn (University Children's Hospital Tübingen, Tübingen, Germany)

Dynamic changes in transcriptome and cytokine expression in melanoma patients treated with combination PD-1 and CTLA-4 inhibitors
Speaker: Su Yin Lim (Macquarie University, Sydney, Australia)

Lunch Break
13:00 - 14:00
Exhibition Hall

Plenary Session
14:00 - 15:30
Gutenberg Hall

Cellular Therapy
Chair: Dolores Schendel (Medigene, Planegg, Germany)
Chair: Harpreet Singh (Immatics Biotechnologies, Tübingen, Germany)

CAR T cells now and then
Speaker: Carl June (University of Pennsylvania, Philadelphia, United States)

New targets and technologies for CAR-T
Speaker: Michael Hudecek (University Medical Center Würzburg, Würzburg, Germany)

Time to get off the shelf- The case for iPSC derived allogeneic cell therapies
Speaker: Hy Levitsky (Century Therapeutics, Seattle, United States)